Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 5/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | SORD | Q00796 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774897 | 0.85 | GAA (0.42) | GRM5ESR1MAPK14GAATDP1 | |
| SCHEMBL21550282 | 0.83 | ESR1 (0.35) | GRM5ESR1ACHEMAPK14JAK2 | |
| SCHEMBL20685774 | 0.83 | MAPK14 (0.42) | GRM5ESR1MAPK14 | |
| SCHEMBL14555163 | 0.80 | KDM4C (0.46) | GRM5TRPV1ACHE | |
| SCHEMBL20612065 | 0.79 | HCAR3 (0.43) | ESR1MAPK14TDP1 | |
| SCHEMBL11306797 | 0.79 | CCR4 (0.34) | GRM5ESR1ACHEJAK2JAK3 | |
| SCHEMBL28277650 | 0.79 | HCAR3 (0.43) | ESR1MAPK14TDP1 | |
| SCHEMBL20956373 | 0.77 | CCR4 (0.36) | GRM5ESR1HTR7 | |
| SCHEMBL19402182 | 0.77 | CFD (0.40) | GRM5SYK | |
| SCHEMBL20677070 | 0.77 | CFD (0.40) | GRM5SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1910159-A | 2,4-diaminopyrimidines and their use for inducing cardiomyogenesis | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| EP-1727806-A1 | 2,4-DIAMINOPYRIMIDINES AND THEIR USE FOR INDUCING CARDIOMYOGENESIS | Novartis AG (CH) | 2006-12-06 | — | — | EP | disclosed |
| US-20050209231-A1 | Compositions and methods for inducing cardiomyogenesis | SCRIPPS RESEARCH INSTITUTE, THE | 2005-09-22 | — | — | US | disclosed |
| WO-2005068437-A1 | 2, 4 - DIAMINOPYRIMIDINES AND THEIR USE FOR INDUCING CARDIOMYOGENESIS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209231-A1 | Compositions and methods for inducing cardiomyogenesis | TNNI3, MYLK2, TNNC1 | GRM5 3791/4885TRPV1 4200/4885ESR1 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.